Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors

Aims: Measurement of protein S (PS) activity in patients taking direct oral anticoagulants (DOACs) using reagents based on a clotting assay results in falsely high PS activity, thus masking inherited PS deficiency, which is most frequently seen in the Japanese population. In this study, we investigated the effect of factor Xa (FXa) inhibitors on PS activity using the reagent on the basis of the chromogenic assay, which was recently developed in Japan. Methods: The study enrolled 152 patients (82 males and 70 females; the average age: 68.5±14.0 years) receiving three FXa inhibitors (rivaroxaban, edoxaban, and apixaban). PS activity was measured using the reagents on the basis of the clotting and chromogenic assays. Results: PS activity measured by the clotting assay reagents exhibited falsely high values depending on the plasma concentrations of FXa inhibitors in patients taking either rivaroxaban or edoxaban. However, none of the three FXa inhibitors affected PS activity when measured using the chromogenic assay. Conclusion: In patients taking rivaroxaban or edoxaban, inherited PS deficiency is likely missed because the levels of PS activity measured using the reagents based on the clotting assay are falsely high. However, we report that three FXa inhibitors do not affect PS activity measured by the chromogenic assay. When measuring the levels of PS activity in patients undergoing DOACs, the principles of each reagent should be understood. Furthermore, plasma samples must be collected at the time when plasma concentrations of DOACs are lowest or the DOAC-Stop reagent should be used.

[1]  R. Marlar,et al.  Pleiotropic anticoagulant functions of protein S, consequences for the clinical laboratory. Communication from the SSC of the ISTH , 2021, Journal of thrombosis and haemostasis : JTH.

[2]  D. Kang,et al.  Racial differences in protein S Tokushima and two protein C variants as genetic risk factors for venous thromboembolism , 2020, Research and practice in thrombosis and haemostasis.

[3]  K. Hayashi,et al.  The effect of direct oral anticoagulants on blood protein C activity , 2020 .

[4]  S. Platton,et al.  Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban , 2018, International journal of laboratory hematology.

[5]  N. Hamasaki,et al.  Protein S-specific activity assay system is not affected by direct oral anticoagulants. , 2018, Thrombosis research.

[6]  B. Châtelain,et al.  Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests , 2018, TH Open.

[7]  W. Ageno,et al.  Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians , 2018, Journal of thrombosis and haemostasis : JTH.

[8]  Jeannie K. Lee,et al.  Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. , 2017, Clinical therapeutics.

[9]  S. Connolly,et al.  Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review , 2017, JAMA cardiology.

[10]  G. Raskob,et al.  Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism , 2016, Thrombosis and Haemostasis.

[11]  R. Gosselin,et al.  The laboratory's 2015 perspective on direct oral anticoagulant testing , 2016, Journal of thrombosis and haemostasis : JTH.

[12]  J. Dogné,et al.  Edoxaban: Impact on routine and specific coagulation assays , 2015, Thrombosis and Haemostasis.

[13]  G. Lippi,et al.  Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors , 2015, Seminars in Thrombosis & Hemostasis.

[14]  G. Lippi,et al.  Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? , 2015, Clinical chemistry and laboratory medicine.

[15]  C. Frost,et al.  A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban , 2014, Clinical pharmacology : advances and applications.

[16]  W. Coucke,et al.  Influence of dabigatran and rivaroxaban on routine coagulation assays , 2014, Thrombosis and Haemostasis.

[17]  H. Büller,et al.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. , 2014, Blood.

[18]  D. Coyle,et al.  Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. , 2014, JAMA.

[19]  C. Weiss,et al.  Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[20]  T. Miyata,et al.  Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. , 2013, Thrombosis research.

[21]  N. Hamasaki,et al.  Activated Protein C Anticoagulant System Dysfunction and Thrombophilia in Asia , 2012, Annals of laboratory medicine.

[22]  A. Griesmacher,et al.  Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests , 2012, Clinical chemistry and laboratory medicine.

[23]  J. Harenberg,et al.  Determination of the anticoagulant effects of new oral anticoagulants: an unmet need , 2012, Expert review of hematology.

[24]  N. Hamasaki,et al.  New quantitative total protein S-assay system for diagnosing protein S type II deficiency: clinical application of the screening system for protein S type II deficiency , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[25]  C. Hesse,et al.  Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time , 2011, Thrombosis and Haemostasis.

[26]  T. Lindahl,et al.  Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays , 2011, Journal of thrombosis and haemostasis : JTH.

[27]  Yukiko Sato,et al.  Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. , 2009, Thrombosis research.

[28]  J. Griffin,et al.  Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry , 2008, Thrombosis and Haemostasis.

[29]  Y. Kokubo,et al.  Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers , 2006, Journal of thrombosis and haemostasis : JTH.

[30]  N. Hamasaki,et al.  Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. , 2005, Clinical biochemistry.

[31]  T. Miyata,et al.  Prevalence of protein S deficiency in the Japanese general population: The Suita Study , 2004, Journal of thrombosis and haemostasis : JTH.

[32]  J. Douketis,et al.  Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair , 2002 .

[33]  D. Siegal,et al.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review , 2017, Chest.

[34]  E. Favaloro,et al.  The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. , 2016, Pathology.

[35]  E. Calzolari,et al.  Sublocalization of the human protein C gene on chromosome 2q13–q14 , 2004, Human Genetics.